SEC filing record
Primary Source · SEC.gov

Klothea Bio, Inc.

2024 vintageRule 506(b)Filing record

Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.

Latest signalSold increasedForm D/A · 2026-09-088 events: 3 sold increased, 3 investors increased, 1 offering downsizedLast filing 2026-09-08

Raised

$7M

Investors

22

Min Invest

None stated

AltStreet Verified Issuer badge

Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.

What this filing shows

·

Every sentence is a value as filed on SEC Form D

Klothea Bio, Inc. is a Delaware corporation organized in 2024 that first filed a Form D on October 28, 2024 and most recently amended it on September 8, 2026 in the Other Health Care industry group. The offering claims Rule 506(b) and covers debt. Klothea Bio, Inc. reported $6,885,000 sold from 22 investors of a $10,385,000 total offering as of the Form D filed September 8, 2026. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated. The Form D names Scott Hamilton Ryan (CRD 7097428), associated with Finalis Securities, LLC as the recipient of sales compensation soliciting in all states. Sales commissions are reported as $12,500 and finders' fees as $0. Form D allows these to be estimates. The issuer's address of record is 195 Nw 40th Street, Miami, FL 33127.

EDGAR Filing Data

Form D — Primary Source

View on SEC.gov
CIK Number0002042705
Entity NameKlothea Bio, Inc.
ExemptionRule 506(b)
What the exemption meansRule 506(b) of Regulation D: securities may be sold to an unlimited number of accredited investors and up to 35 non-accredited investors who meet the rule's sophistication standard, without general solicitation or advertising.
Entity TypeCorporation
Jurisdiction of OrganizationDelaware
Year Organized2024
Issuer Address195 Nw 40th Street, Miami, FL 33127
Phone(305) 846-9027
Industry / Fund TypeOther Health Care
Securities TypeDebt
First Sale DateOctober 11, 2024
Filing DateSeptember 8, 2026
Accession Number0002042705-26-000005
Total Offering Amount$10,385,000
Total Amount Sold$6,885,000
Amount Remaining$3,500,000
Total Investors22
Non-Accredited InvestorsNone
Minimum Investment$0 (no stated minimum)
Offering DurationIntended to last more than one year
Sales Commissions$12,500 (to Scott Hamilton Ryan)
Finders' Fees$0
Proceeds to Related Persons$0
Revenue RangeDecline to Disclose
State (Issuer Address)FL
Amendment Count4 filings on record
Signed ByJeffrey B. Madden, President

Filings on Record

Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.

In the Terminal

Filing events

8

latest Sep 8, 2026

Critical / warning

0 / 1

4 watch · 3 info

Statements extracted

0

none on file

NAV prints

0

none on file

Offering chains

1

raising

Latest event Sold increase · Sep 8, 2026

SEC.gov
Open in the terminal Watch this issuerInvestor $149/mo unlocks the values; Pro $349/mo adds the universe.

Investor

  • 8 filing events with values and deltas, latest 2026-09-08, and alerts on the next one
  • 1 offering timeline: velocity, share raised, first-sale lag, stalled flags

Pro

  • This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
  • The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV

Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

Jeffrey B. Madden

Executive Officer, Director · Miami, FL

Agustin Fernandez Santana III

Executive Officer, Director · Miami, FL

Olivier Jarry

Executive Officer · Miami, FL

Walter Schmidt

Director · Miami, FL

Petr Sramek

Director · Miami, FL

Placement Agents and Sales Compensation (Form D)

Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.

Scott Hamilton RyanCRD 7097428 on BrokerCheck

Associated broker-dealer: Finalis Securities, LLC (CRD 305908) · New York, NY · Soliciting in all states

Questions About Klothea Bio, Inc.

Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.

What is Klothea Bio, Inc.?

Klothea Bio, Inc. is a Delaware corporation organized in 2024 that filed a Form D with the SEC on September 8, 2026 in the Other Health Care industry group. The filing claims Rule 506(b) for an offering of debt.

Is Klothea Bio, Inc. legit?

AltStreet does not rate legitimacy; it reports the public record. Klothea Bio, Inc. filed a Form D with the SEC on September 8, 2026 claiming Rule 506(b). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $6,885,000 sold to 22 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.

Is Klothea Bio, Inc. registered with or approved by the SEC?

No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Klothea Bio, Inc. claimed Rule 506(b) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.

How much has Klothea Bio, Inc. raised?

Klothea Bio, Inc. reported $6,885,000 sold from 22 investors of a $10,385,000 total offering as of the Form D filed September 8, 2026.

Who can invest in Klothea Bio, Inc.?

The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated.

What is the minimum investment in Klothea Bio, Inc.?

The Form D lists the minimum investment as $0, which means the issuer did not state a minimum on the form. The offering documents, not the Form D, set the actual subscription terms.

Who is selling Klothea Bio, Inc. and how are they paid?

The Form D names Scott Hamilton Ryan (CRD 7097428), associated with Finalis Securities, LLC as the recipient of sales compensation soliciting in all states. Sales commissions are reported as $12,500 and finders' fees as $0. Form D allows these to be estimates.

Who is behind Klothea Bio, Inc.?

The Form D lists 5 related persons: Jeffrey B. Madden, executive officer, director; Agustin Fernandez Santana III, executive officer, director; Olivier Jarry, executive officer; Walter Schmidt, director; Petr Sramek, director. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.

Where is Klothea Bio, Inc. located?

The issuer's address on its SEC filings is 195 Nw 40th Street, Miami, FL 33127. Its phone number of record is (305) 846-9027. It is organized under the laws of Delaware.

How long is the Klothea Bio, Inc. offering open?

The issuer indicated that the offering is intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open; 3 amendments are on record for this CIK.

What is Klothea Bio, Inc.'s revenue?

The issuer declined to disclose its revenue range on the Form D, which the form permits.

AltStreet Verified Issuer badge

Is this your company or fund?

Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.

Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.